For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Compass Therapeutics Inc (NASDAQ: CMPX) was $1.75 for the day, up 2.94% from the previous closing price of $1.70. In other words, the price has increased by $2.94 from its previous closing price. On the day, 0.69 million shares were traded. CMPX stock price reached its highest trading level at $1.78 during the session, while it also had its lowest trading level at $1.68.
Ratios:
Our analysis of CMPX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 14.96 and its Current Ratio is at 14.96. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On February 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $12.
On February 19, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $12.Piper Sandler initiated its Overweight rating on February 19, 2025, with a $12 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 09 ’25 when GORDON CARL L sold 3,571,428 shares for $1.59 per share. The transaction valued at 5,678,571 led to the insider holds 0 shares of the business.
ORBIMED ADVISORS LLC sold 3,571,428 shares of CMPX for $5,678,571 on Apr 09 ’25. The Director now owns 0 shares after completing the transaction at $1.59 per share. On Apr 09 ’25, another insider, OrbiMed Genesis Master Fund, L, who serves as the Director of the company, bought 3,571,428 shares for $1.59 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CMPX now has a Market Capitalization of 241993504 and an Enterprise Value of 121906368. For the stock, the TTM Price-to-Sale (P/S) ratio is 284.69 while its Price-to-Book (P/B) ratio in mrq is 1.93. Its current Enterprise Value per Revenue stands at 143.419 whereas that against EBITDA is -2.176.
Stock Price History:
The Beta on a monthly basis for CMPX is 1.21, which has changed by 0.17449665 over the last 52 weeks, in comparison to a change of 0.05430484 over the same period for the S&P500. Over the past 52 weeks, CMPX has reached a high of $4.08, while it has fallen to a 52-week low of $0.76. The 50-Day Moving Average of the stock is -29.80%, while the 200-Day Moving Average is calculated to be -4.57%.
Shares Statistics:
CMPX traded an average of 1.66M shares per day over the past three months and 1765690 shares per day over the past ten days. A total of 137.82M shares are outstanding, with a floating share count of 87.84M. Insiders hold about 36.48% of the company’s shares, while institutions hold 39.25% stake in the company. Shares short for CMPX as of 1743379200 were 6618254 with a Short Ratio of 3.98, compared to 1740700800 on 3695821. Therefore, it implies a Short% of Shares Outstanding of 6618254 and a Short% of Float of 6.75.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Compass Therapeutics Inc (CMPX) is presently subject to a detailed evaluation by 9.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.05 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.19 and -$0.66 for the fiscal current year, implying an average EPS of -$0.47. EPS for the following year is -$0.5, with 9.0 analysts recommending between -$0.21 and -$0.76.
Revenue Estimates
Based on 10 analysts’ estimates, the company’s revenue will be $30.01M in the next fiscal year. The high estimate is $77.77M and the low estimate is $3.8M.
